General effect of low-dose tamsulosin (0.2 mg) as a first-line treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia: a systematic review and meta-analysis

References

• Teodorovich OV, Lutsevich OE, Galliamov EA, et al. [Characteristics and results of retroperitoneoscopic operations in urology]. Urologiia 2006;(4):24-7
   PubMedGoogle Scholar
• Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118-40
   PubMed Web of Science ®Google Scholar
• McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011;185:1793-803
   PubMed Web of Science ®Google Scholar
• Lee E. Comparison of tamsulosin and finasteride for lower urinary tract symptoms associated with benign prostatic hyperplasia in Korean patients. J Int Med Res 2002;30:584-90
   PubMed Web of Science ®Google Scholar
• Lee E, Lee C. Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 1997;80:606-11
   PubMedGoogle Scholar
• Li NC, Chen S, Yang XH, et al. Efficacy of low-dose tamsulosin in Chinese patients with symptomatic benign prostatic hyperplasia. Clin Drug Investig 2003;23:781-7
   PubMed Web of Science ®Google Scholar
• Na YJ, Guo YL, Gu FL. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. J Med 1998;29:289-304
   PubMedGoogle Scholar
• Park CH, Chang HS, Oh BR, et al. Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a nonblind multicentre Korean study. Clin Drug Investig 2004;24:41-7
   PubMed Web of Science ®Google Scholar
• Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int 2006;97(Suppl 2):34-8, discussion 44-5
   PubMed Web of Science ®Google Scholar
• Giuliano F. Lower urinary tract symptoms and sexual dysfunction: a common approach. BJU Int 2008;97(Suppl 3):22-6
   Google Scholar
• Ren RM, Kou M, Lan XX. Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia: a meta analysis. Chin Med J 2010;123:234-8
   PubMed Web of Science ®Google Scholar
• Yuan J, Liu Y, Yang Z, et al. The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews. Curr Med Res Opin 2013;29:279-87
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S. The Cochrane Collaboration: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. 2011. Available at: http://www.cochrane-handbookorg
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Contr Clin Trials 1986;7:177-88
   PubMedGoogle Scholar
• Gotoh M, Kamihira O, Kinukawa T, et al. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. BJU Int 2005;96:581-6
   PubMed Web of Science ®Google Scholar
• Joo KJ, Sung WS, Park SH, et al. Comparison of alpha-blocker monotherapy and alpha-blocker plus 5alpha-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia. J Int Med Res 2012;40:899-908
   PubMed Web of Science ®Google Scholar
• Lee HS, Kim SW, Oh SJ, et al. Efficacy and safety of tamsulosin for treating lower urinary tract symptoms associated with benign prostatic hyperplasia: a multicenter, randomized, controlled, open-label non-inferiority study. Korean J Urol 2012;53:178-83
   PubMedGoogle Scholar
• Okada H, Kamidono S, Yoshioka T, et al. A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. BJU Int 2000;85:676-81
   PubMed Web of Science ®Google Scholar
• Ju XB, Wu HF, Su JT. The clinical efficacy of naftopidil tablet in the treatment of benign prostatic hyperplasia. Nat J Androl 2002;8:286-8
   Google Scholar
• Kawabe K, Yoshida M, Homma Y. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006;98:1019-24
   PubMed Web of Science ®Google Scholar
• Yu HJ, Lin AT, Yang SS, et al. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). BJU Int 2011;108:1843-8
   PubMed Web of Science ®Google Scholar
• Hanyu S, Hatano A, Nishiyama T, et al. [A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia]. Hinyokika kiyo Acta Urologica Japonica 2010;56:489-94
   PubMedGoogle Scholar
• Kurita Y, Masuda H, Suzuki K, et al. Transition zone ratio and prostate-specific antigen density as predictors of the response of benign prostatic hypertrophy to alpha blocker and anti-androgen therapy. Br J Urol 1997;80:78-83
   PubMedGoogle Scholar
• Masumori N, Tsukamoto T, Iwasawa A, et al. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urol Int 2009;83:49-54
   PubMed Web of Science ®Google Scholar
• Zhang K, Yu W, Jin J, et al. Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study. Urology 2011;78:636-40
   PubMed Web of Science ®Google Scholar
• Kim JH, Park JY, Oh MM, et al. Treatment satisfaction with low-dose tamsulosin for symptomatic benign prostatic hyperplasia: results from a multicentre cross-sectional survey. Int J Clin Pract 2012;66:1209-15
   PubMed Web of Science ®Google Scholar
• Sun YH, Liu ZY, Zhang ZS, et al. Long-term efficacy and safety of tamsulosin hydrochloride for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: data from China. Chin Med J 2011;124:56-60
   PubMed Web of Science ®Google Scholar
• Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol 1995;76:325-36
   PubMedGoogle Scholar
• Bird ST, Delaney JA, Brophy JM, et al. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40–85 years in the United States: risk window analyses using between and within patient methodology. BMJ 2013;347:f6320
   PubMedGoogle Scholar
• Ramirez J. Severe hypotension associated with alpha blocker tamsulosin. BMJ 2013;347:f6492
   PubMedGoogle Scholar
• Chapple CR, Wyndaele JJ, Nordling J, et al. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 1996;29:155-67
   PubMed Web of Science ®Google Scholar
• Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998;51:901-6
   PubMed Web of Science ®Google Scholar
• Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998;51:892-900
   PubMed Web of Science ®Google Scholar
• Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2003;170(2 Pt 1):498-502
   PubMed Web of Science ®Google Scholar
• Debruyne FM, Van der Poel HG. Clinical experience in Europe with uroselective alpha1-antagonists. Eur Urol 1999;36(Suppl 1):54-8, discussion 65
   PubMedGoogle Scholar
• Goktas S, Kibar Y, Kilic S, et al. Recovery of abnormal ejaculation by intermittent tamsulosin treatment. J Urol 2006;175:650-2, discussion 52-3
   PubMed Web of Science ®Google Scholar
• Naruganahalli KS. Abnormal ejaculation associated with tamsulosin in benign prostatic hyperplasia patients. Expert Opin Investig Drugs 2006;15:1635-8
   PubMed Web of Science ®Google Scholar
• Barqawi AB, Myers JB, O’Donnell C, Crawford ED. The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms. BJU Int 2007;100:853-7
   PubMed Web of Science ®Google Scholar
• Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900
   PubMed Web of Science ®Google Scholar
• Ioannidis JP. Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. Can Med Assoc J 2009;181:488-93
   PubMed Web of Science ®Google Scholar
• Barry MJ, Fowler FJ Jr, Mulley AG Jr, et al. Patient reactions to a program designed to facilitate patient participation in treatment decisions for benign prostatic hyperplasia. Med Care 1995;33:771-82
   PubMed Web of Science ®Google Scholar
• Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995;154:1770-4
   PubMed Web of Science ®Google Scholar
• Füllhase C, Chapple C, Cornu JN, et al. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol 2013;64:228-43
   PubMed Web of Science ®Google Scholar